In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support.
introduction
Although survival in patients with locally advanced adenocarcinoma of the pancreas (APC) is still largely unsatisfactory, however, the availability of gemcitabine (GEM) has represented a major progress in the medical management of APC. In fact, GEM-based chemotherapy (CT) represents the gold standard for systemic treatment of advanced pancreatic cancer for the majority of patients, being able to improve cancer-related symptoms and patient's PS and to confer a modest survival advantage [1] . Combination regimens incorporating GEM, cisplatin (CDDP), 5-fluorouracil (5-FU), oxaliplatin (OXP), or irinotecan (CPT11) have generally shown to improve outcomes in objective response rates but with little or no improvement in survival parameters in phase III trials [1, 2] . Today a significant percentage of APC patients progressing after GEM-based CT are still in relatively good clinical conditions and may require a second-and even a third-line therapy. Therefore, several off-label drugs shown to be active in advanced APC are employed regularly in daily clinical practice even if no specifically addressed trial has scientifically demonstrated their efficacy in terms of symptoms palliation and survival parameters.
Phase II trials evaluating second-line chemotherapy (SLCT) in patients failing GEM-based CT are relatively scarce in medical literature. Some agents, such as paclitaxel, OXP, CPT11, capecitabine (CAP), rubitecan, pemetrexed, and flutamide, have been tested as single agents [1, 2] . Other drugs shown to be active in first-line have been tested in combination regimens as SLCT. At present, there is no standard SLCT for patients who have become refractory to GEM, although a recently reported study has indicated that the OXP/5-FU/leucovorin regimen is superior to best supportive care (BSC) in these patients [1, 2] .
In this paper we report a retrospective survey of the efficacy and toxicity of SLCT employed in daily clinical practice in a series of unselected patients affected by APC progressing after GEM-based first-line treatment.
patients and methods

patient population
Enrolled patients had to shown APC progressing after GEM-based first-line treatment. Patients were enrolled into the study if they satisfied the symposium article 
efficacy assessment
Partial response (PR), stable disease (SD), and progressive disease (PD) were determined according to the WHO criteria [3] . The sum of PR and SD was reported as tumor growth control rate (TGCR). TtP was estimated from the date of first treatment to the first evidence of PD. OS was estimated from the date of first treatment to the date of death or the last follow-up. Clinical benefit assessment was based on patients and physician-reported improvement of cancer-related symptoms and/or stabilization of improvement of PS.
treatment schedule
The CT schedules were as follows: intravenous (i. toxicity Adverse events were graded according to the National Cancer Institute common toxicity. If multiple toxic effects were observed, the dose administered was based on the most severe toxicity experienced. The dose adjustment schedule was evaluated at the beginning of a new administration. Dose reductions were carried out as previously described [3] . OXP was reduced in the event of persistent paresthesia/dysesthesia between cycles or with pain lasting for >7 days according to cancer center guidelines and staff physician's decision. When paresthesia/dysesthesia with either pain or functional impairment persisted between cycles, OXP was discontinued.
statistical analysis
Objective responses were reported as their relative rates adjusted to the nearest unit with 95% confidence interval. TtP and OS were calculated as previously described [3] .
results patient characteristics
Forty-two patients were collected from nine Gruppo Oncologico Italia Meridionale centers (Table 1 ). There were 26 males and 16 females with a median age of 63 years and a median PS of one according to the ECOG scale. Five patients (12%) had a PR to front-line treatment, and 16 patients (38%) had SD. All patients except seven had stage IV APC, and 62% had multiple sites of disease. Liver metastases were present in 67% of patients, locoregional lymph nodes in 57%, lung metastases in 14%, and peritoneal carcinomatosis in 33% of patients.
antitumor activity and survival
As shown in Table 2 there were six objective PR (14%), and 16 patients (38%) had an SD for a TGCR of 62%. No complete response was recorded. Median duration of PR was 5.4 months (range 2-8). Median TtP from the start of second-line treatment was 4 months (range 1-7 months). No correlation has been found between length of TtP during first-line CT and length of TtP in SLCT or objective response. It had been proposed that the activity of an SLCT could be documented by showing that the TtP following SLCT is longer than the TtP following front-line therapy in each single patient. The ratio of TtPs has been defined as the growth modulation index (GMI) with each patient being his own control [4] . A GMI >1 means that TtP was longer with the SLCT and treatment that produces a GMI ‡1.33 (33% improvement) should be considered to have excellent activity [5] . In this series 11 patients (26%) had a GMI >1.33, and two further patients had a GMI = 1. Median OS from the start of front-line therapy was 6.7 months (2 to 9+ months). Twenty-seven patients (64%) had a stabilization of PS or a subjective improvement of cancer-related symptoms.
tolerability and safety
Patients had received between 2 and 12 cycles. Median delivered dose intensity was higher than 90% in the whole series. Most patients received full treatment. Twenty patients had some treatment delay, but only three patients experienced more than two cycle delay. Reasons for delay were not treatment related in six cases. Reasons for treatment discontinuation were PD in all patients but three cases. Two patients had grade 3-4 toxicity which precluded continuation of CT and one patient refused to continue for psychological distress.
Overall, side-effects were moderate and easily manageable. Grade 3 anemia was recorded in 14% of patients, grade 3-4 neutropenia occurred in 17% of patients (two cases of febrile neutropenia). Thrombocytopenia occurred in seven patients and was severe in three cases (7%) with massive liver disease. Most of the non-hematological symptoms were mild being less than grade 3. Mild OXP-related peripheral sensory neurotoxicity occurred only in five patients (12%) most probably due to the low median number of CT cycles administered. Mild hand-foot syndrome was observed in two cases.
discussion
Several GEM-based regimens have been recently tested where GEM is given in association with other agents [1] [2] [3] . This paper reports the results of a retrospective survey on the efficacy and safety of the FOLFOX4 regimen as SLCT in a series of 42 nonconsecutive patients progressing after GEM-based first-line therapy. In this series of unselected patients the FOLFOX4 regimen yielded a 14% PR rate with 38% of patients showing SD for a TGCR of 57%. Median duration of PR was 5.2 months, while median TtP and OS were 4 and 6.7 months, respectively. The activity in terms of GMI (GMI ‡ 1.33 in 26% of cases) in the evaluation of palliative treatment of APC is interesting, but it should be interpreted with caution.
Overall, these data support the use of SLCT in patients with good PS progressing after a front-line CT. These data should, however, be interpreted with caution because SLCT has been evaluated in a few trials. Various OXP-based regimens have been tested in seven phase II trials involving relatively small numbers of patients. The impact of the addition of OXP to GEM was tested in 31 patients failing single-agent GEM who achieved a PR in 23% of cases and an SD >2 months in 35% of cases [6] . Median TtP and OS were 4.2 and 6.0 months, respectively. Other investigators carried out a phase II trial involving 18 patients treated with OXP and c.v.i. 5-FU [7] . There were no PR and three patients (17%) had an SD with poor survival. In a series of 41 patients treated with raltitrexed/OXP, 10 patients (24%) yielded a PR and 11 had SD with a progression-free survival (PFS) at 6 months of 14.6%, and a median OS of 5.2 months [8] . A clinically relevant improvement of quality of life was observed in numerous domains. OS was significantly longer in patients with previous PFS >6 months and in patients without pancreatic localization, raising the issue of selecting patients who may be more likely to benefit from salvage treatment. A weekly combination of OXP, leucovorin, and 5-FU has been tested in a phase II study in a series of 30 patients achieving a PR in 23.3% of cases, and SD in 30.0% of patients with a median OS of 25 weeks and an improvement in PS in 43% of patients [9] . Patients who had responded to first-line GEM were found more likely to respond or stabilize their disease with SLCT. A phase II trial of OXP plus CAP in a series of 41 patients reported a PR in one case and SD in eight patients with a median OS of 5.8 months, and a 6-month and 1-year survival rate of 48% and 22%, respectively [10] . Toxicity was, however, significant. Preliminary results of another trial of OXP/5-FU in a series of 23 patients have shown an OS of 4 months [11] . Finally, it is worth mentioning the phase III trial by Oettle et al. [12] , comparing OXP/5-FU/folinic acid with BSC in GEM-refractory APC. Median OS of SLCT was 21 weeks in the treatment arm compared with 10 weeks in the BSC arm (P = 0.007). By demand from participating centers the BSC arm was thus closed early.
Because of the good activity shown by camphotecins, CPT11-containing regimens have also received significant attention. In a trial including 25 patients treated with an OXP/CPT11 combination, one patient had a PR and six patients (24%) attained a CBR [13] . Median survival from the start of this regimen was 5.6 months. A series of 38 patients were treated with raltitrexed/CPT11, reporting a 16% ORR and 32% SD rate with a median PFS of 4.0 months and a median OS of 6.5 months [14] . A retrospective evaluation of the four-drug G-FLIP (gemcitabine, 5-fluorouracil, leucovorin, and cisplatin) regimen reported a TGCR of 47% with 24% of PR among 34 patients [4] . Median TtP was of 3.9 months and the OS of 10.3 months. A retrospective analysis of 20 consecutive patients treated with GEM/5-FU/leucovorin/CDDP every 2 weeks reported two patients with a PR and two with an SD despite PD with prior GEM-based therapy [15] . These data support the hypothesis that adding a single new drug such as CPT11 to the same first-line CT upon disease progression may be an important alternative for the treatment of relapsed/resistant cancer.
In conclusion, data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of APC patients. Data from medical literature support the use of SLCT, although its use should be carefully proposed to patients with good PS or those who had a good response to first-line therapy. A prospective randomized trial using a controlled arm without treatment would be needed to definitely demonstrate and validate the place of second-line treatment in progressing APC.
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